Confounding by indication?

Epidemiology

Volumn 8, Issue 1, 1997, Pages 110-

  Shapiro, Samuel ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; HUMAN; NOTE; RANDOMIZED CONTROLLED TRIAL; STOMACH TUMOR;

CIMETIDINE; CONFOUNDING FACTORS (EPIDEMIOLOGY); HISTAMINE H2 ANTAGONISTS; HUMANS; RANITIDINE; STOMACH NEOPLASMS;

EID: 0030641309     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Walker AM. Confounding by indication (Editorial). Epidemiology 1996;7: 335-336.
2. Colin-Jones DG, Langman MJS, Lawson DH, Vessey MP. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance. BMJ 1982;285:1311-1313.
3. Johnson AG, Jick SS, Perera DR, Jick H. Histamine-2 receptor antagonists and gastric cancer. Epidemiology 1996;7:434-436.
4. Süsser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991;133:635-648.
5. Slone D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD. Drug evaluation after marketing. Ann Intern Med 1979;90:257-261.
6. Shapiro S. Case-control surveillance. In: Strom BL, ed. Pharmacoepidemiology. 2nd ed. Chichester, UK: John Wiley and Sons, 1994;301-322.
7. Shapiro S. Do trans fatty acids increase the risk of coronary artery disease? A critique of the epidemiological evidence. Am J Clin Nutr (in press).